person · Reporting owner
Maunsell Farris Maryanne
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HAEMONETICS CORPHAE · Entity 3953 | VP, Chief Accounting Officer | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HAEMONETICS CORP
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,242 |
Reported balance
After 2026-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-05 · Tax withholding · Disposed 259 · Balance 6,242 F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2: This number includes unvested RSUs previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
F2: This number includes unvested RSUs previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 20:19 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 259 | $71.28 | $18,461.52 |
DisclosureSEC source: 0000313143-26-000068 · form4.xml · nonDerivative · entry 1 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,242 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:33 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,220 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000313143-26-000045 · form4.xml · nonDerivative · entry 2 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,501 F3 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F4 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:33 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 197 | $56.29 | $11,089.13 |
DisclosureSEC source: 0000313143-26-000045 · form4.xml · nonDerivative · entry 1 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,281 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,662 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-017102 · form4.xml · nonDerivative · entry 1 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,478 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. Two-thirds of the RSUs vest in two equal annual installments beginning on the first anniversary of the date of grant and one-third of the RSUs vests based on the Issuer's common stock price at the end of a two-year performance period. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2025 Filed May 19, 2025 21:12 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 68 | $70.31 | $4,781.08 |
DisclosureSEC source: 0001127602-25-014941 · form4.xml · nonDerivative · entry 2 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,016 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 1,732 | $0.00 Strike: $70.31 | $0.00 |
DisclosureSEC source: 0001127602-25-015070 · form4.xml · derivative · entry 2 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,732 Underlying: Common Stock · 1,732 shares Expires 2032-05-16 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:31 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-015070 · form4.xml · nonDerivative · entry 1 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,816 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:12 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 60 | $69.38 | $4,162.80 |
DisclosureSEC source: 0001127602-25-014941 · form4.xml · nonDerivative · entry 1 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,084 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 17, 2024 Filed May 21, 2024 22:05 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 1,291 | $0.00 Strike: $95.73 | $0.00 |
DisclosureSEC source: 0001127602-24-016177 · form4.xml · derivative · entry 2 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,291 Underlying: Common Stock · 1,291 shares Expires 2031-05-17 F4 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 17, 2024 Filed May 21, 2024 22:05 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-016177 · form4.xml · nonDerivative · entry 1 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,144 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2024 Filed May 17, 2024 21:05 UTC | HAEMONETICS CORP HAE · Entity 3953 | Tax withholdingCommon Stock | 73 | $96.49 | $7,043.77 |
DisclosureSEC source: 0001127602-24-015876 · form4.xml · nonDerivative · entry 1 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 557 F1 · shares: Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I. F2 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 1,425 | $0.00 Strike: $89.16 | $0.00 |
DisclosureSEC source: 0001127602-23-015948 · form4.xml · derivative · entry 2 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,425 Underlying: Common Stock · 1,425 shares Expires 2030-05-15 F3 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:36 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-015948 · form4.xml · nonDerivative · entry 1 Maunsell Farris Maryanne · CIK 0001950052 · VP, Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 630 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.